SARS-CoV-2: Vaccine Hesitancy among Underrepresented Racial and Ethnic Groups with HIV in Miami, Florida

Deborah L Jones¹, Ana S. Salazar², Violeta J Rodriguez³, Raymond R. Balise⁴, Claudia Uribe Starita², Kristiana Morgan⁴,⁵, Patricia D Raccamarich², Emily Montgomerie², Nicholas Fonseca Nogueira², Irma Barreto Ojeda², Marissa Maddalon⁶, Nicolle L Yanes Rodriguez¹, Theodora Brophy⁵, Thais Martinez⁵, Maria L Alcaide² *

¹Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA
²Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
³Department of Psychology, University of Georgia, Athens, Georgia, USA
⁴Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA
⁵University of Miami Miller School of Medicine, Miami, Florida, USA
⁶University of Miami School of Nursing and Health Studies, Miami, Florida, USA

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Corresponding Author:

Maria L. Alcaide, MD
Professor of Clinical Medicine
Director, Infectious Diseases Research Unit and CFAR Clinical Core
Division of Infectious Diseases, Department of Medicine
University of Miami Miller School of Medicine
1120 NW 14 Street, Miami, Fl. 33136 CRB 864 (D-90A)
T: 305.243.8434
F:305-243-2732
Email: malcaide@med.miami.edu

Alternate Corresponding author

Deborah L. Jones, PhD
Professor of Psychiatry
Department of Psychiatry & Behavioral Sciences,
University of Miami Miller School of Medicine
1400 NW 10th AVE, Miami, Fl. 33136
T: 305.243.2041 E: d.jones3@med.miami.edu
Abstract

**Background:** SARS-CoV-2 and HIV disproportionally affect underrepresented ethnoracial groups in the US. Medical mistrust and vaccine hesitancy will likely impact acceptability of SARS-CoV-2 vaccines. This study examined SARS-CoV-2 vaccine hesitancy among underrepresented ethnoracial groups with HIV and identified factors that may reduce vaccine uptake.

**Methods:** We conducted a cross-sectional study of adults ≥18 years with HIV residing in Miami, FL. Participants were invited to participate in the ACTION (A Comprehensive Translational Initiative on Novel Coronavirus) cohort study. A baseline survey was administered from April-August 2020 and followed by a COVID-19 vaccine hesitancy survey from August-November 2020. The COVID-19 vaccine hesitancy survey was adapted from the Strategic Advisory Group Experts survey. Comparisons by race and ethnicity were performed using the Freedman-Haltmann extension of Fisher’s exact test

**Results:** A total of 94 participants were enrolled, mean age 54.4 years, 52% female, 60% Black non-Latinx, and 40% non-Black Latinx. Black non-Latinx participants were less likely to agree that vaccinations are important for health when compared to non-Black Latinx (67.8% vs 92.1%, p=0.009), less likely to agree that vaccines are effective in preventing disease (67.8% vs 84.2%, p=0.029), less likely to believe that vaccine information is reliable and trustworthy (35.7% vs 71.1%, p=0.002), and less likely to believe vaccines were unnecessary because COVID-19 would disappear soon (11% vs 21%, p=0.049).

**Conclusion:** Medical mistrust, vaccine hesitancy and negative sentiments about SARS-CoV-2 vaccines are prevalent among underrepresented ethnoracial groups with HIV, particularly Black non-Latinx. Targeted strategies to increase vaccine uptake in this population are warranted.

**Key Words:** COVID-19, HIV, vaccine hesitancy, underrepresented racial and ethnic groups
**Introduction**

Since its emergence in late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly around the world as the causative agent of the COVID-19 pandemic. As of March 2021, the total confirmed cases globally of SARS-CoV-2 infection have reached 114.5 million with 2.54 million related deaths. Although containment strategies such as lockdown and social distancing have contributed to the decrease in transmission rates of COVID-19, there is still a large number of individuals that are vulnerable to waves of infection.

In order to mitigate the harmful effects of the virus on public health and the global economy, remarkable efforts have been made to accelerate the development of an effective and safe vaccine against SARS-CoV-2 (COVID-19 vaccine). As of December 2020, more than 40 COVID-19 candidate vaccines were being studied in human trials, 10 of which are in phase III, and several with emergency use authorization. Vaccination is one of the most successful public health interventions as it helps prevent over 2 million deaths annually across all age groups. It is estimated that community immunity against SARS-CoV-2 infection would be achieved when at least 70% of the population are immune, either through vaccination or after natural infection. Therefore, achieving high rates of vaccine coverage is one of the highest impact strategies to end the morbidity and mortality caused by the COVID-19 pandemic.

Vaccine hesitancy denotes the spectrum of decision-making that falls between delay in acceptance and outright refusal of vaccination. Hesitation regarding the use of a vaccine or willingness to be vaccinated against COVID-19 poses a critical challenge for global health. Successful vaccination strategies focus on increasing education and awareness about
vaccination within the general public, improving access to and affordability of vaccination, engaging stakeholders, and increasing transparency of the risks and benefits of being vaccinated to ultimately stop viral transmission.\textsuperscript{6,12,13} Thus, anticipating and working to address hesitancy towards a COVID-19 vaccine can facilitate public uptake and lead to higher rates of vaccination among target populations.

Once an epicenter for COVID-19, the US State of Florida continues to have high number of new cases with a daily average of 10,000 cases per 100,000 and 100 deaths.\textsuperscript{2,14} Furthermore, the county of Miami-Dade continues to rank highest in incidence and prevalence of HIV in the U.S.\textsuperscript{15} Both, SARS-CoV-2 and HIV viruses disproportionally affect underrepresented racial and ethnic groups in the US, especially Black non-Latinx individuals.\textsuperscript{16} Black individuals living in Miami comprise 17.7\% of the population, yet account for more than 40\% of those living with HIV in Miami-Dade. Thus, high COVID-19 vaccination coverage is crucial to address health disparities from this pandemic among Black Non-Latinx individuals. However, medical mistrust, vaccine hesitancy and negative sentiments about a COVID-19 vaccine will likely play a significant role in reducing acceptability and uptake of a vaccine by Black Non-Latinx and other underrepresented ethnic groups with HIV.\textsuperscript{17,18}

Patterns of abuse and exploitation at the hands of practitioners and researchers alike have persisted since colonial times.\textsuperscript{19} Perhaps the most famous example of medical mistrust in the Black community dates back to the Tuskegee Syphilis Study,\textsuperscript{20} in which researchers withheld treatment from Black men in order to study the natural history of syphilis. This historical context influences months of civil unrest against systemic racism in the US and globally during the COVID-19 pandemic and may play a role in increasing medical and public health mistrust.\textsuperscript{21} Medical and public health mistrust around COVID-19 has been prevalent in the
United States, however, greater COVID-19 mistrust has been reported among people with HIV (PWH), particularly in underrepresented ethnoracial groups. These factors may act as barriers to healthcare uptake, e.g., vaccines, preventive care, health care use, and adherence, and contribute to stigma, adverse health consequences, and health disparities. This study examines factors underlying COVID-19 vaccine hesitancy among PWH in order to identify factors that may delay the uptake of vaccine. Results will inform the design of vaccine campaigns and strategies to enhance COVID-19 vaccine uptake in underrepresented ethnoracial groups with HIV.

Methods

Ethical Approval

Ethical approval for this study was obtained from the University of Miami (UM) Institutional Review Board (number: 20200340). Verbal informed consent via telephone was obtained prior to conducting any study related assessments. All procedures were followed in accordance with the ethical standards of the University and with the Helsinki Declaration of 1975, as revised in 2013. Informed consent was obtained from all participants for being included in the study.

Participants

To qualify for the study, participants needed to be fluent in English or Spanish, have a history of HIV, at least 18 years or older and currently living in Miami, Florida. Participants were enrolled in the ACTION study (A Comprehensive Translational Initiative on Novel Coronavirus), a cohort of PWH and SARS-CoV-2 coinfection, living in Miami. The ACTION study recruited PWH through an existing registry created by the Miami Center for HIV Research in Mental Health (CHARM) and the Center for AIDS Research (CFAR).
Participants were also recruited directly from the community with the use of printed flyers, spoken word, and referrals from medical professionals. All CHARM/CFAR registry participants were PWH. All ACTION participants (N=231) were invited to participate, 176 of them completed the survey, of which 102 were from underrepresented ethnoracial groups. Participants not recruited from the registry provided HIV test results, clinician notes, a list of antiretroviral medications, or copies of laboratory results prior to enrollment. SARS CoV-2 infection was confirmed by a commercially approved PCR test.

**Design**

This cross-sectional study utilized an adapted COVID-19 survey for PWH. This survey was developed by MWCCS investigators and is in the public domain and available at https://bit.ly/3l0irDJ. The vaccine hesitancy survey was constructed from a twenty-item questionnaire integrating the standardized approach developed by the World Health Organization Strategic Advisory Group of Experts (WHO SAGE) working on vaccine hesitancy. Some questions were revised to incorporate COVID-19. Sociodemographic information and measures of vaccine confidence (trust/belief), complacency (perceived risk or benefit), convenience (access), and willingness to get vaccinated were included in the survey. Participants completed a baseline survey during the months of April to August 2020, and a follow-up survey with a supplemental vaccine hesitancy questionnaire during the months of August-November 2020. The 25 minute survey was administered by telephone by the study staff or it was self-administered by accessing a unique web link via REDCap. Participants were offered an incentive of $15 for completing the survey.
Variables / Measures

COVID-19 survey. The COVID-19 baseline survey is an adaptation from the survey used in the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS), which evaluated COVID-19 burden among PWH in the US and other settings.\textsuperscript{26,32,33} This questionnaire includes sociodemographic information such as sex, gender, race, ethnicity, employment status, living situation, and monthly household income. Options for race included White, Black, and Other. Options for ethnicity included Hispanic (Latinx), non-Hispanic (non-Latinx), and Other.

Vaccine hesitancy scale (see Supplementary Material). Ten questions from the Vaccine Hesitancy Scale (VHS)\textsuperscript{28} were included and used a five-point Likert: 1=strongly agree; 2=agree 3=neutral; 4=disagree; and 5=strongly disagree. One of these ten questions was adapted to expand the perceived risk\textsuperscript{11} measure specific to COVID-19: “I do not need vaccines for coronavirus as it will disappear soon”. Additional binary yes/no questions were included based on the Health Belief Model\textsuperscript{34} to assess general attitudes towards vaccines, vaccine-related conspiracy beliefs, trust or distrust in medical and governmental institutions, and perceived risk or benefit of a COVID-19 vaccine within the context of HIV infection.

The primary measure for hesitancy or willingness to get vaccinated was assessed via the following yes/no question: “If a COVID-19 vaccine was available would you get vaccinated?”. The last question assessed the number of individuals known to the respondent who had died from COVID-19.

Statistical Analysis

All data were interrogated using graphical and numeric exploratory data analysis methods. Responses with percentages are reported by ethnoracial group (Black non-Latinx and non-Black Latinx). Group differences were explored using the Freedman-Haltmann extension to
Fisher’s exact test to handle small cell frequencies. Further, Cochran–Mantel–Haenszel methods were used after grouping the vaccine hesitancy five-point Likert scale into three groups, agree/unsure/disagree, to consider the rank order of the responses. Both methods afforded similar inferences. Bivariate logistic regression models predicting willingness to get vaccinated by vaccine hesitancy items and ethnoracial groups as well as their two-way interaction were built.

The association between the belief/trust questions and the willingness to get vaccinated question “If a vaccine to prevent COVID-19 infection was available, would you get vaccinated?” was explored using logistic regression methods, with a nominal p-value of <0.05 considered statistically significant. The three-level willingness to get vaccinated variable was converted to a binary yes vs. unsure/no indicator. Bivariate models, using each predictor along with ethnoracial groups and the predictor by ethnoracial group interaction, were built. To ease interpretation and to minimize handle small cell frequencies, ordinal predictors were converted to binary variables (yes vs. unsure/no) and univariate odds ratios with Wald p-values and 95% confidence intervals (95% CI) are reported for all except one variable. All data were collected and stored using REDCap software.35,36 Analyses were accomplished using R software (version 4.0.3)37 with the tidyverse (1.3)38, janitor39 and REDCap40 packages.
Results

Sociodemographic Characteristics

A total of 94 participants were enrolled. Participants were primarily from two ethnoracial groups 56/94 (60%) Black non-Latinx and 38/94 (40%) non-Black Latinx. Due to the low number of Latinx Black and White non-Latinx (n=8), those ethnoracial groups were not included in the analysis. Sociodemographic characteristics by ethnoracial group are presented in Table 1. Overall, 52% of participants were female, 72% were unemployed, 82% were living on their own, and 61% earned less than USD$1,000 per month.

Vaccine Hesitancy Scale by Ethnoracial Groups

Vaccine hesitancy items by ethnoracial groups are presented in Table 2. Black non-Latinx participants were less likely to agree with vaccinations being important for their health when compared with non-Black Latinx (68% vs 92%, respectively $p=0.009$). Black non-Latinx were also less likely to agree with the statement that vaccines are effective in preventing disease (68% Black non-Latinx agreed, 84% non-Black Latinx agreed; $p=0.029$). A substantially lower proportion of Black non-Latinx (36%) compared to non-Black Latinx (71%) reported believing that vaccine information is reliable and trustworthy ($p=0.002$). A lower proportion of Black non-Latinx (11%) were less likely to believe that vaccines were unnecessary because COVID-19 would disappear soon compared with Latinx non-Black (21%) ($p=0.049$).

Vaccine Hesitancy Scale Predicting Willingness to Get Vaccinated

There were no interactions between ethnoracial groups and the Vaccine Hesitancy Scale items, except for the statement “Vaccines are effective in preventing disease” ($p=0.237$). For non-Black Latinx participants, there was a linear relationship between increasing Likert
responses and the belief in the statement. Predicted probabilities ranged from 0.89 for those who responded “strongly agree” to 0.008 for those who responded “strongly disagree”. Among Black non-Latinx participants, the relationship between vaccine hesitancy and willingness to be vaccinated was diminished with probabilities of 0.57 and 0.25.

Agreeing or strongly agreeing with vaccines being important for health, as well as agreeing or strongly agreeing with vaccines being effective were both associated with greater odds of being willing to get vaccinated overall (OR=12.00 [95% 3.22, 44.79], p<0.001 and OR=5.1 [95% 1.78, 14.59], p=0.001, respectively). Agreeing or disagreeing with “Getting vaccinated is important for my health and the health of others in my community” and “All vaccines offered by the government program in my community are important for good health” were similarly associated with 8-fold greater odds of willingness to get vaccinated (OR=8.00 [95% 2.11, 30.28], p<0.001 and OR=8.36 [95% 2.77, 25.22], p=0.001, respectively). Agreeing or strongly agreeing that information about vaccines is reliable and trustworthy was associated with over 6-fold greater odds of willingness to get vaccinated (OR=6.76 [95% 2.71, 16.88], p=0.001). Agreeing or strongly agreeing with the statement about following doctors’ recommendations about vaccines was associated with over 5-fold greater odds of willingness to get vaccinated (OR=5.28 [95% 1.57, 17.71], p=0.001). Likewise, agreeing or disagreeing with “Getting vaccines is a good way to protect myself from disease” was associated with over 7-fold greater odds of being willing to get vaccinated OR=7.07 [95% 2.14, 23.42], p<0.001). No other items were associated with being willing to get vaccinated.

Beliefs about COVID-19 vaccination by ethnoracial group were not different and are presented in Table 3. No statistically significant differences by ethnoracial group emerged.
Many participants (42%) knew someone who died from COVID-19. The most common response was the death of a friend (22%).

**Discussion**

This study examined COVID-19 vaccine hesitancy and its impact on willingness to be vaccinated among PWH from underrepresented ethnoracial groups in Miami, Florida, a city with high incidence and prevalence of HIV and COVID-19. Overall, both Black non-Latinx and non-Black Latinx with HIV reported high vaccine acceptance, but Black non-Latinx were more hesitant towards vaccination in general. Similarly, Black non-Latinx were more concerned about risks and side effects associated with new vaccines. Among both ethnoracial groups, willingness to get vaccinated was greater among PWH who believed that vaccines are effective in preventing diseases, important for health, and a good way to protect one’s self. Additionally, willingness to be vaccinated was higher among those who believed that vaccines are reliable and trustworthy, and recommended by doctors.

Similar to another study, our data also suggests that vaccine hesitancy towards COVID-19 vaccines is high among Black non-Latinx living with HIV and may constitute a barrier for vaccine uptake. Health-related mistrust is a byproduct of the intersection between the history of Black communities, systemic racism, and their interaction with the healthcare system. Black and Latinx individuals may face social and economic vulnerabilities and higher rates of comorbidities. In our sample, a substantial proportion of participants reported being unemployed and with low income, which has been associated with limited access to medications and missed medical appointments in previous studies in this ethnoracial group. Furthermore, within the context of the COVID-19 pandemic, these underrepresented groups also have higher rates of SARS-CoV-2 infections and/or COVID-19
morbidity and mortality compared to the general population while also experiencing financial and social strains. Therefore, it is critically important to increase prevention efforts among underrepresented groups in the US.

Despite the availability of a vaccine, vaccination alone cannot control the spread of COVID-19 if community members are unwilling to be vaccinated. Interestingly, while more almost 60% of Black non-Latinx participants in our study thought that their current health status made it important for them to get a COVID-19 vaccine, they were highly hesitant of getting vaccinated. As such, the lower acceptance among underrepresented groups living with HIV accentuates the need for rapid implementation of targeted strategies to avoid exacerbating existing health disparities within these communities. Additionally, most participants agreed to do what their doctor or health care provider would recommend about vaccines for their health. Previous studies have identified social service and healthcare providers as a trusted source for information, and PWH were more likely to get vaccinated if a doctor recommended the vaccine. Furthermore, PWH were much more likely (8-fold increase) to be vaccinated if they felt it important for the community. Therefore, strategies that target patient-provider relationships focused on reducing misinformation as well as messaging targeted towards community health could promote COVID-19 vaccine uptake among PWH.

Vaccines are an effective prevention strategy and a COVID-19 vaccine should have the potential to control the spread of the highly contagious and lethal SARS-CoV-2 virus. In our study, while most participants believed that vaccines were important for the good health of others and the community, a large majority of Black non-Latinx participants reported not finding the information about the vaccine program reliable and trustworthy. Traditionally,
individuals of the lowest income categories are less trustful of the health care community and are more likely to rely on unofficial sources such as social media to make their medical decisions.\textsuperscript{46,47} While it is challenging to estimate the effect and the extent to which these sources influence people’s thoughts, it is essential that stakeholders, public education and outreach put significant efforts to counteract any disinformation and to address potential concerns to enable individuals to make informed decisions.

Limitations of this study include a convenient sample, small sample size, limited time frame for data collection prior to availability of a vaccine and limited racial and ethnic representation from the Southern US, where rates of HIV among Whites are low. This limits generalizability. In addition, some variables were dichotomized due to small cell sizes during the analysis. Despite these limitations, our findings suggest avenues for targeting potential barriers to COVID-19 vaccination. Health disparities may increase unless the root causes and the components of this complex issue are understood so they can be approached with focused strategies and advocacy. Larger studies using nationally representative samples of underrepresented ethnoracial groups living with HIV are needed to inform interventions that address mistrust and COVID-19 health disparities.

In summary, our study is among the first to report vaccine hesitancy among a vulnerable population, such as underrepresented ethnoracial groups living with HIV. Targeted strategies to increase vaccine acceptability and uptake in the US are urgently needed. More specifically, stakeholders should focus on enhancing patient-provider relationships, reducing misinformation, and leveraging social norms to overcome mistrust towards COVID-19 vaccination.
Author’s Contributions

All authors had full access to all the data in the study and take responsibility for the accuracy and the integrity of the data analysis. MLA and DJ were responsible for study concept and design. All authors were responsible for data acquisition and interpretation of results. RRB and VJR contributed with the data analyses. All authors were responsible for drafting and critical revision of the manuscript for important intellectual content.

Declaration of Interest

MLA is currently receiving a grant (#P30AI073961) from the Miami Center for AIDS Research (CFAR). DLJ is currently receiving a grant (#P30MH116867) from the Clinic HIV/AIDS Registry of Miami (CHARMS). For the remaining authors none were declared.

Funding

This work was supported by National Institutes of Health grants through the University of Miami Center for AIDS Research (CFAR) (grant number P30AI073961 to MLA) and the Center for HIV and Research in Mental Health (CHARM) (grant number P30MH116867 to DLJ). VJR’s work on this manuscript was partially supported by a Ford Foundation Fellowship, administered by the National Academies of Sciences, Engineering, and Medicine.

Data availability: The data underlying this article will be shared on reasonable request to the corresponding author.
References

1. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. *J Clin Med.* 2020;9(4).

2. Johns Hopkins University Center for Systems Science and Engineering. Coronavirus COVID-19 Global Cases. 2020; [https://coronavirus.jhu.edu/us-map](https://coronavirus.jhu.edu/us-map). Accessed July 02, 2020.

3. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med.* 2020. [https://www.ncbi.nlm.nih.gov/pubmed/32663912](https://www.ncbi.nlm.nih.gov/pubmed/32663912). Accessed Jul 14.

4. Krammer F. SARS-CoV-2 vaccines in development. *Nature.* 2020;586(7830):516-527.

5. World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020; [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). Accessed December, 2020.

6. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. *Lancet.* 2020;396(10263):1614-1616.

7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *The New England journal of medicine.* 2020;383(27):2603-2615.

8. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in immunology.* 2020;11:585354.

9. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *The New England journal of medicine.* 2020;383(20):1920-1931.

10. World Health Organization. Immunization. Dec 2019; [https://www.who.int/news-room/facts-in-pictures/detail/immunization](https://www.who.int/news-room/facts-in-pictures/detail/immunization). Accessed December 2, 2020.

11. Macdonald NE. Vaccine hesitancy: Definition, scope and determinants. *Vaccine.* 2015;33(34):4161-4164.
12. World Health Organization. Strategies for Addressing Vaccine Hesitancy - A Systematic Review. 2014; https://www.who.int/immunization/sage/meetings/2014/october3_SAGE_WG_Strategies_addressing_vaccine_hesitancy_2014.pdf. Accessed Dec 3, 2020.

13. Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ, Hesitancy SWGoV. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015;33(34):4180-4190.

14. Florida Department of Health. Florida COVID-19 Response. 2020; https://floridahealthcovid19.gov. Accessed June 10, 2020.

15. Florida Department of Health. HIV/AIDS. 2019; http://miamidade.floridahealth.gov/programs-and-services/infectious-disease-services/hiv-aids-services/. Accessed June 30, 2020.

16. Dyer O. Covid-19: Black people and other minorities are hardest hit in US. In: British Medical Journal Publishing Group; 2020.

17. Geoghegan S, O'Callaghan KP, Offit PA. Vaccine Safety: Myths and Misinformation. Front Microbiol. 2020;11:372.

18. Jaiswal J, Halkitis PN. Towards a More Inclusive and Dynamic Understanding of Medical Mistrust Informed by Science. Behav Med. 2019;45(2):79-85.

19. Washington HA. Medical apartheid: The dark history of medical experimentation on Black Americans from colonial times to the present. Doubleday Books; 2006.

20. Park J. Historical Origins of the Tuskegee Experiment: The Dilemma of Public Health in the United States. Ui sahak. 2017;26(3):545-578.

21. Wade L. An unequal blow. Science. 2020;368(6492):700-703.

22. Hoyt MA, Rubin LR, Nemeroff CJ, Lee J, Huebner DM, Proeschold-Bell RJ. HIV/AIDS-related institutional mistrust among multiethnic men who have sex with men: effects on HIV testing and risk behaviors. Health Psychol. 2012;31(3):269-277.
23. Bogart LM, Ojikutu BO, Tyagi K, et al. COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV. 2021;86(2):200-207.

24. Williamson LD, Bigman CA. A systematic review of medical mistrust measures. Patient Educ Couns. 2018;101(10):1786-1794.

25. Powell W, Richmond J, Mohottige D, Yen I, Joslyn A, Corbie-Smith G. Medical Mistrust, Racism, and Delays in Preventive Health Screening Among African-American Men. Behav Med. 2019;45(2):102-117.

26. D'Souza G, Springer G, Gustafson D, et al. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study. HIV Res Clin Pract. 2020:1-10.

27. SAGE working group dealing with vaccine hesitancy (March 2012 to November 2014). (March 2012 to November 2014); https://www.who.int/immunization/sage/sage_wg_vaccine_hesitancy_apr12/en/, 2020.

28. Shapiro GK, Tatar O, Dube E, et al. The vaccine hesitancy scale: Psychometric properties and validation. Vaccine. 2018;36(5):660-667.

29. Shapiro GK, Holding A, Perez S, Amsel R, Rosberger Z. Validation of the vaccine conspiracy beliefs scale. Papillomavirus Research. 2016;2:167-172.

30. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Research. 2020;288:198114.

31. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.

32. Jones DL, Ballivian J, Rodriguez VJ, et al. Mental health, coping, and social support among people living with HIV in the Americas: A comparative study between Argentina and the USA during the SARS-CoV-2 pandemic. In: Research Square; 2020.
33. MACS/WIHS Combined Cohort Study (MWCCS). https://statepi.jhsph.edu/mwccs/about-mwccs/, 2020.

34. Cheney MK, John R. Underutilization of Influenza Vaccine: A Test of the Health Belief Model. SAGE Open. 2013;3(2):2158244013484732.

35. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of biomedical informatics. 2009;42(2):377-381.

36. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. Journal of biomedical informatics. 2019;95:103208.

37. R Development Core Team. R: A language and environment for statistical computing [computer program]. R Foundation for Statistical Computing; 2016.

38. Hester J. Welcome to the Tidyverse. Journal of Open Source Software. 2019;4(43):1686.

39. Firke S. janitor: Simple tools for examining and cleaning dirty data. R package version 2.0. 1. In:2020.

40. tidyREDCap: Helper Functions for Working with REDCap Data. [computer program]. Version R package version 0.2.0.2020.

41. Kalichman SC, Kalichman MO. HIV-Related Stress and Life Chaos Mediate the Association Between Poverty and Medication Adherence Among People Living with HIV/AIDS. J Clin Psychol Med Settings. 2016;23(4):420-430.

42. Harris RA, Xue X, Selwyn PA. Housing Stability and Medication Adherence among HIV-Positive Individuals in Antiretroviral Therapy: A Meta-Analysis of Observational Studies in the United States. J Acquir Immune Defic Syndr. 2017;74(3):309-317.

43. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495.
44. Andrasik MP, Chandler C, Powell B, et al. Bridging the divide: HIV prevention research and Black men who have sex with men. *Am J Public Health*. 2014;104(4):708-714.

45. Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. *Hum Vaccin Immunother*. 2013;9(8):1763-1773.

46. Gowda C, Dempsey AF. The rise (and fall?) of parental vaccine hesitancy. *Hum Vaccin Immunother*. 2013;9(8):1755-1762.

47. Callender D. Vaccine hesitancy: More than a movement. *Hum Vaccin Immunother*. 2016;12(9):2464-2468.
Table 1. Demographic Characteristics of 94 Participants with HIV Living in Miami, Florida
Stratified by Ethnoracial Groups

| Characteristics     | Non-Black Latinx | Black Non-Latinx | Overall |
|---------------------|------------------|------------------|---------|
|                     | N (%)            | N (%)            | N (%)  |
| Total               | 38 (100)         | 56 (100)         | 94 (100)|
| Age                 |                  |                  |         |
| Mean (SD)           | 51.3 (11.4)      | 56.4 (10.8)      | 54.4 (11.3)|
| Median [Min, Max]   | 51.0 [27.0, 68.0] | 59.5 [27.0, 71.0]| 57.0 [27.0, 71.0]|
| Sex                 |                  |                  |         |
| Male                | 23 (60.5)        | 22 (39.3)        | 45 (47.9)|
| Female              | 15 (39.5)        | 34 (60.7)        | 49 (52.1)|
| Employed            |                  |                  |         |
| Yes                 | 17 (44.7)        | 9 (16.1)         | 26 (27.7)|
| No                  | 21 (55.3)        | 47 (83.9)        | 68 (72.3)|
| Living Situation    |                  |                  |         |
| Own place           | 32 (84.2)        | 45 (80.4)        | 77 (81.9)|
| Characteristics       | Non-Black Latinx | Black Non-Latinx | Overall  |
|-----------------------|------------------|------------------|----------|
|                       | N (%)            | N (%)            | N (%)    |
| Total                 | 38 (100)         | 56 (100)         | 94 (100) |
| Someone else’s house  | 6 (15.8)         | 11 (19.6)        | 17 (18.1) |
| Monthly Household Income |                 |                  |          |
| ≤$1000                | 18 (47.4)        | 39 (69.6)        | 57 (60.6) |
| ≥$1000                | 20 (52.6)        | 17 (30.4)        | 37 (39.4) |
Table 2. Vaccine Hesitancy Scale Items by Ethnoracial Groups Living in Miami, Florida

|                                      | Non-Black Latinx N (%) | Black Non-Latinx N (%) | p    |
|--------------------------------------|------------------------|------------------------|------|
| Vaccination is important for my health |                        |                        |      |
| Strongly agree                       | 19 (50.0)              | 18 (32.1)              | 0.009|
| Agree                                | 16 (42.1)              | 20 (35.7)              |      |
| Neutral                              | 2 (5.3)                | 11 (19.6)              |      |
| Disagree                             | 0 (0.0)                | 3 (5.4)                |      |
| Strongly Disagree                    | 1 (2.6)                | 4 (7.2)                |      |
| Vaccines are effective in preventing disease |                    |                        |      |
| Strongly agree                       | 17 (44.7)              | 18 (32.1)              |      |
| Agree                                | 15 (39.5)              | 20 (35.7)              |      |
| Neutral                              | 5 (13.2)               | 8 (14.3)               |      |
| Disagree                             | 1 (2.6)                | 7 (12.5)               | 0.029|
| Strongly Disagree                    | 0 (0.0)                | 3 (5.4)                |      |
| Getting vaccinated is important for my health and the health of others in my community | | | |
| Strongly agree                       | 18 (47.4)              | 18 (32.4)              |      |
| Agree                                | 14 (36.8)              | 27 (48.2)              |      |
| Neutral                              | 5 (13.2)               | 4 (7.1)                |      |
| Disagree                             | 1 (2.6)                | 5 (8.9)                |      |
| Strongly Disagree                    | 0 (0.0)                | 2 (3.6)                | 0.283|
| All vaccines offered by the government program in my community are important for good health | | | |
| Strongly agree                       | 16 (42.1)              | 12 (21.4)              |      |
| Agreement Level | Frequency (Percentage) | Frequency (Percentage) | p-value |
|----------------|------------------------|------------------------|---------|
| Agree          | 14 (36.8)              | 26 (46.5)              | 0.117   |
| Neutral        | 7 (18.4)               | 11 (19.6)              |         |
| Disagree       | 1 (2.6)                | 4 (7.1)                |         |
| Strongly Disagree | 0 (0.0)             | 3 (5.4)                |         |

The information I receive about vaccines from the vaccine program is reliable and trustworthy.

| Agreement Level | Frequency (Percentage) | Frequency (Percentage) | p-value |
|----------------|------------------------|------------------------|---------|
| Strongly agree | 9 (23.7)               | 7 (12.5)               | 0.002   |
| Agree          | 18 (47.4)              | 13 (23.2)              |         |
| Neutral        | 6 (15.8)               | 18 (32.1)              |         |
| Disagree       | 3 (7.8)                | 17 (30.4)              |         |
| Strongly Disagree | 2 (5.3)            | 1 (1.8)                |         |

Generally, I do what my doctor or health care provider recommends about vaccines for my health

| Agreement Level | Frequency (Percentage) | Frequency (Percentage) | p-value |
|----------------|------------------------|------------------------|---------|
| Strongly agree | 20 (52.6)              | 16 (28.6)              |         |
| Agree          | 15 (39.5)              | 26 (46.4)              |         |
| Neutral        | 1 (2.6)                | 8 (14.3)               |         |
| Disagree       | 2 (5.3)                | 5 (8.9)                |         |
| Strongly Disagree | 0 (0.0)            | 1 (1.8)                | 0.077   |

I do not need vaccines for coronavirus at it will disappear soon

| Agreement Level | Frequency (Percentage) | Frequency (Percentage) | p-value |
|----------------|------------------------|------------------------|---------|
| Strongly agree | 2 (5.3)                | 5 (8.9)                |         |
| Agree          | 2 (5.3)                | 7 (12.5)               |         |
| Neutral        | 10 (26.3)              | 20 (35.7)              |         |
| Disagree       | 13 (34.2)              | 13 (23.3)              |         |
| Strongly Disagree | 11 (28.9)            | 11 (19.6)              | 0.049   |

Getting vaccines is a good way to protect myself from disease.

| Agreement Level | Frequency (Percentage) | Frequency (Percentage) |
|----------------|------------------------|------------------------|
| Strongly agree | 18 (47.4)              | 17 (30.9)              |
| Agree          | 14 (36.8)              | 24 (43.6)              |
| Response         | Count 1 | Count 2 | p-value |
|------------------|----------|----------|---------|
| Neutral          | 5 (13.2) | 7 (12.8) |         |
| Disagree         | 1 (2.6)  | 6 (10.9) |         |
| Strongly Disagree| 0 (0.0)  | 1 (1.8)  | 0.132   |
| New vaccines carry more risks than older vaccines |         |         |
| Strongly agree   | 9 (23.7) | 10 (17.9)|         |
| Agree            | 9 (23.7) | 13 (23.2)|         |
| Neutral          | 15 (39.5)| 25 (44.6)|         |
| Disagree         | 5 (13.2) | 4 (7.1)  |         |
| Strongly Disagree| 0 (0.0)  | 4 (7.2)  | 0.614   |
| I am concerned about serious adverse effects of vaccines |         |         |
| Strongly agree   | 12 (31.6)| 12 (21.4)|         |
| Agree            | 15 (39.5)| 28 (50.0)|         |
| Neutral          | 5 (13.2) | 9 (16.1) |         |
| Disagree         | 5 (13.2) | 6 (10.7) |         |
| Strongly Disagree| 1 (2.5)  | 1 (1.8)  | 0.810   |
Table 3. Beliefs About COVID-19 Vaccination of 94 Participants with HIV Living in Miami, Florida
Stratified by Ethnoracial Groups

| Items                                                                 | Non-Black Latinx | Black Non-Latinx | $p$    |
|-----------------------------------------------------------------------|------------------|------------------|--------|
|                                                                        | N (%)            | N (%)            |        |
| Total                                                                 | 38 (100)         | 56 (100)         |        |
| Do you believe a vaccine could be an effective way to prevent a COVID-19 infection? |                  |                  |        |
| Yes                                                                   | 28 (73.7)        | 28 (50.0)        | 0.067  |
| No                                                                    | 4 (10.5)         | 8 (14.3)         |        |
| Unsure                                                                | 6 (15.8)         | 20 (35.7)        |        |
| If a vaccine to prevent COVID-19 infection was available would you get vaccinated? |                  |                  |        |
| Yes                                                                   | 25 (65.8)        | 26 (47.3)        | 0.057  |
| No                                                                    | 5 (13.1)         | 15 (27.3)        |        |
| Unsure                                                                | 8 (21.1)         | 14 (25.4)        |        |
| Do you feel that your current health status or other health conditions would make it unsafe to get a COVID-19 vaccine? |                  |                  | 0.894  |
| Yes                                                                   | 12 (31.6)        | 15 (27.3)        |        |
| No                                                                    | 18 (47.4)        | 25 (45.4)        |        |
| Unsure                                                                | 8 (21.0)         | 15 (27.3)        |        |
| Do you feel that your current health status or other health conditions make it important for you to get a COVID-19 vaccine? |                  |                  | 0.288  |
| Yes                                                                   | 25 (65.8)        | 32 (57.1)        |        |
| No                                                                    | 8 (21.0)         | 18 (32.2)        |        |
| Unsure                                                                | 5 (13.2)         | 6 (10.7)         |        |
| If getting vaccinated was a requirement to go back to your daily activities (working, traveling, public places), would you get vaccinated? |                  |                  |        |
|                | Group 1 | Group 2 |
|----------------|---------|---------|
| **Yes**        | 32 (84.2) | 38 (67.8) |
| **No**         | 5 (13.2)  | 9 (16.1)  |
| **Unsure**     | 1 (2.6)   | 9 (16.1)  |

Do you feel that healthcare professionals, government, local authorities or leaders may force you into getting vaccinated?

|                | Group 1 | Group 2 |
|----------------|---------|---------|
| **Yes**        | 18 (47.4) | 19 (33.9) |
| **No**         | 17 (44.7) | 27 (48.2) |
| **Unsure**     | 3 (7.9)   | 10 (17.9) |

0.214

0.387